- Previous Close
0.0390 - Open
0.0360 - Bid 0.0360 x --
- Ask 0.0380 x --
- Day's Range
0.0360 - 0.0360 - 52 Week Range
0.0330 - 0.0780 - Volume
2,347 - Avg. Volume
132,472 - Market Cap (intraday)
5.206M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
3.60 - EPS (TTM)
0.0100 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer's disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases. The company was incorporated in 2002 and is based in Perth, Australia.
www.neuroscientific.comRecent News: NSB.AX
View MorePerformance Overview: NSB.AX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NSB.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NSB.AX
View MoreValuation Measures
Market Cap
5.64M
Enterprise Value
1.15M
Trailing P/E
4.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.13
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.89
Financial Highlights
Profitability and Income Statement
Profit Margin
53.66%
Return on Assets (ttm)
14.08%
Return on Equity (ttm)
27.00%
Revenue (ttm)
2.21M
Net Income Avi to Common (ttm)
1.19M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.49M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
639.12k